Doctors for Drug Policy Reform Calls for Regulation of Intoxicating Hemp-Derived Cannabinoids
A group of physicians known as Doctors for Drug Policy Reform (D4DPR) is urging for the regulation of intoxicating hemp-derived cannabinoids, including delta-8 THC. The group argues that the safety of products containing this compound is unknown and that it should be subject to a regulatory framework.
In a recent policy paper released by D4DPR, the group states, “Our stance at D4DPR is that all intoxicating cannabinoids should be subject to a regulatory framework to ensure public safety.” The group, formerly known as Doctors for Cannabis Regulation, notes that the legalization of hemp with the 2018 Farm Bill may have unintentionally legalized the production of intoxicating minor cannabinoids like delta-8 THC.
However, the legislation did not include provisions for regulating these compounds, leading to a thriving industry of unregulated products in many areas. The group points out that delta-8 THC, which is chemically synthesized from hemp CBD, is now widely available in various retail outlets such as gas stations, CBD shops, convenience stores, smoke shops, and online platforms.
To address this issue, D4DPR is calling on policymakers to develop and enact a regulatory framework for all intoxicating cannabinoids, regardless of their source. The group has several recommendations for these regulations, including only allowing the sale of intoxicating compounds by licensed dispensaries and implementing appropriate taxation to fund public health initiatives and regulatory oversight.
The group also recommends that sales of intoxicating cannabinoids be restricted to adults aged 21 and older and that these products be sold in child-resistant packaging with clear labeling about their intoxicating effects. Additionally, the group suggests including the International Intoxication Cannabinoid Product Symbol (a silhouette of a cannabis leaf) on packaging to indicate the product’s contents in a graphic form.
Furthermore, D4DPR is calling for mandatory lab testing of intoxicating cannabinoid products for purity, potency, and safety, with certificates of analysis available for consumer inspection. The group also recommends conducting research on the clinical safety and toxicology of minor cannabinoids, as many of these compounds have not been thoroughly studied.
